Photocure ASA: Results for the fourth quarter of 2021
Oslo, Norway, 23 February 2022: Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 94.2 million in the fourth quarter of 2021 (Q4 2020: NOK 97.7 million). Unit sales in the U.S. and Europe rose 11% and 12%, respectively, while the revenue comparison was impacted by a one-time reversal of an accrual in the prior-year period and foreign exchange. Photocure has a solid pipeline of anticipated Blue Light Cystoscopy (BLC) tower installations in the U.S. and expects placements to accelerate during the second half of 2022.“Photocure showed strong execution and resilience